Partnerships: Industry & Academic

Engaging Industry and Academic Partners

CCTG is known for cancer clinical trial research and is the world's largest cooperative collaborative oncology group. Our success is realized through our network of investigators who develop scientifically important and meaningful trials, conducted both rapidly and to rigorous standards. With over 40 years of experience there is no network that rivals the depth and breadth of operations with a global reputation for rapid execution of quality clinical trials.

Partnerships

- A national program of the [Canadian Cancer Society](https://www.cancer.ca)
- [National Clinical Trials Network](https://www.cancerresearchuk.org/national-clinical-trials-network) - The only non-American partner of the National Institute of Health
- [Cancer Research Institute (CRI)](https://www.cancerresearchuk.org/cancer-research/cancer-research-institute) - Clinical Accelerator and Scientific Leadership Committee

National and international collaboration

- [European Organization for Research and Treatment of Cancer (EORTC)](https://www.eortc.be) - Response Evaluation Criteria in Solid Tumours (RECIST) working group
- [The Gynecological Cancer Intergroup](https://www.eortc.be)
- [The Breast Cancer Intergroup (BIG)](https://www.eortc.be)
- [Australasian Lung Cancer Trials Group (ALTG)](https://www.eortc.be)
- [Intergroup Francophone de Cancerologie, Thoracique (IFCT)](https://www.eortc.be)
- [Canadian Tissue Repository Network (CTRNeT)](https://www.eortc.be)

Industry partnerships

While CCTG trials are independently conducted, analyzed and reported. Pharmaceutical or
academic drug manufacturers provide CCTG access to their investigational new drugs because they recognize the high quality research being conducted through the group.

The collaboration between CCTG and AZ, which has been ongoing since 2015, provides an opportunity to accelerate the development of new immunotherapy approaches by combining expertise and resources between industry and academia. The expected synergy will ultimately benefit patients with a number of different tumor types, where new and more effective therapies are clearly needed.

Giovanni Melià, MD, Head of Immuno-Oncology, Global Medical Affairs, AstraZeneca.